Market Place
Sourcing Support
Cullinan Presents CLN-978 Preclinical Data at ACR Convergence
14 Nov 2024 //
GLOBENEWSWIRE
Cullinan Therapeutics Q3 2024 Results & Corporate Update
07 Nov 2024 //
GLOBENEWSWIRE
Cullinan to Participate Chat at Stifel 2024 Healthcare Conference
05 Nov 2024 //
GLOBENEWSWIRE
Cullinan Therapeutics to CLN-978 Data at ACR Convergence 2024
04 Nov 2024 //
GLOBENEWSWIRE
Cullinan Receives FDA Clearance For CLN-978 In Lupus Erythematosus
16 Oct 2024 //
GLOBENEWSWIRE
Cullinan Submits IND For CLN-978 To Treat Lupus
16 Sep 2024 //
GLOBENEWSWIRE
Cullinan Therapeutics Presents Zipalertinib Phase 2b Data At ESMO 2024
14 Sep 2024 //
GLOBENEWSWIRE
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
Cullinan Therapeutics Reports Q2 2024 Results And Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
Cullinan Returns Bispecific To Harbour BioMed After $25M US Rights Deal
08 Aug 2024 //
FIERCE BIOTECH
Cullinan`s Zipalertinib Shows Positive Pivotal Phase 2b REZILIENT1 Data
01 Jun 2024 //
GLOBENEWSWIRE
Cullinan Td Cowen Fireside Chat: Oncology Innovation Summit Participation
24 May 2024 //
GLOBENEWSWIRE
Cullinan Cln-619 First Data: Anti-Mica/B With Cpi At Asco 2024
23 May 2024 //
GLOBENEWSWIRE
Cullinan Provides Update, Reports Q1 2024 Financial Results
15 May 2024 //
GLOBENEWSWIRE
Cullinan Appoints Mary Kay Fenton as CFO
29 Apr 2024 //
GLOBENEWSWIRE
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
25 Apr 2024 //
FINANCE YAHOO
Cullinan Presents CLN-619 Combo Data at ASCO 2024
24 Apr 2024 //
GLOBENEWSWIRE
Cullinan changes name, pivots to autoimmune disease
17 Apr 2024 //
BIOPHARMADIVE
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
16 Apr 2024 //
GLOBENEWSWIRE
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
16 Apr 2024 //
GLOBENEWSWIRE
Cullinan Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 2024 //
GLOBENEWSWIRE
Cullinan Oncology Announces FDA Clearance of Investigational NDA for CLN-619
01 Mar 2024 //
GLOBENEWSWIRE
Cullinan Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
18 Dec 2023 //
GLOBENEWSWIRE
Cullinan Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617
14 Dec 2023 //
GLOBENEWSWIRE
Cullinan Oncology Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Cullinan to Present Data Demonstrating Progress Across Immunotherapy-Pipeline
03 Nov 2023 //
GLOBENEWSWIRE
Cullinan Oncology to Participate in Upcoming Investor Conferences
30 Oct 2023 //
GLOBENEWSWIRE
Cullinan Oncology to Participate in Upcoming Investor Conferences
06 Sep 2023 //
GLOBENEWSWIRE
Cullinan Oncology Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Cullinan Oncology Announces First Patient Dosed in Phase 1 Evaluating CLN-978
09 Aug 2023 //
GLOBENEWSWIRE
Cullinan Oncology to Participate in Upcoming Investor Conferences
31 Jul 2023 //
GLOBENEWSWIRE
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619
25 May 2023 //
GLOBENEWSWIRE
Cullinan Oncology Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Cullinan Oncology to Present First Clinical Data Novel Anti-MICA/B Antibody
26 Apr 2023 //
GLOBENEWSWIRE
Cullinan Oncology to Participate in Stifelâ 2023 Targeted Oncology Days
20 Apr 2023 //
GLOBENEWSWIRE
Cullinan Oncology Announces U.S. FDA Clearance of IND Application for CLN-617
27 Mar 2023 //
GLOBENEWSWIRE
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617
14 Mar 2023 //
GLOBENEWSWIRE
Cullinan Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
09 Mar 2023 //
GLOBENEWSWIRE
Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference
27 Feb 2023 //
GLOBENEWSWIRE
Cullinan Oncology drops $25M upfront for candidate from Harbour
15 Feb 2023 //
ENDPTS
Cullinan plucks U.S. rights to Harbour BioMed`s novel bispecific
14 Feb 2023 //
FIERCE BIOTECH
Cullinan to Participate in the Guggenheim 5th Annual Oncology Conference
02 Feb 2023 //
GLOBENEWSWIRE
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Feb 2023 //
GLOBENEWSWIRE
Cullinan Oncology Announces U.S. FDA Clearance of IND Application for CLN-978
24 Jan 2023 //
GLOBENEWSWIRE
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Jan 2023 //
GLOBENEWSWIRE
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Dec 2022 //
GLOBENEWSWIRE
Cullinan Oncology Provides Corporate Update &Reports 3Q 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Cullinan Oncology Appoints David P. Ryan to its Board of Directors
02 Nov 2022 //
BIOSPACE
Cullinan Oncology to Participate in Upcoming Investor Conferences
01 Nov 2022 //
GLOBENEWSWIRE
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Nov 2022 //
GLOBENEWSWIRE
Cullinan Oncology Significantly Increases Ownership Stake in MICA Subsidiary
25 Oct 2022 //
GLOBENEWSWIRE
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2022 //
GLOBENEWSWIRE
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Sep 2022 //
GLOBENEWSWIRE
Cullinan Oncology Announces Appointment of Jacquelyn Sumer as CLO
15 Aug 2022 //
GLOBENEWSWIRE
Cullinan Oncology Provides Corporate Update and Reports Q2 Financial Results
10 Aug 2022 //
GLOBENEWSWIRE
Cullinan Oncology to Participate in BTIG and Canaccord Conferences
01 Aug 2022 //
GLOBENEWSWIRE
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2022 //
GLOBENEWSWIRE
Cullinan Oncology to Participate in William Blair Biotech Focus Conference
05 Jul 2022 //
GLOBENEWSWIRE
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Jul 2022 //
GLOBENEWSWIRE
Cullinan, Taiho Pharma Complete Agreement for Collaboration on CLN-081/TAS6417
23 Jun 2022 //
GLOBENEWSWIRE
